Pulsed Radiofrequency Ablation and Steroid Injections for the Treatment of Meralgia Paresthetica

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Meralgia Paresthetica (MP) is a mononeuropathy of the lateral femoral cutaneous nerve (LFCN), characterized by pain, numbness, hyperesthesia, or hypoesthesia, especially in the anterolateral thigh where the nerve has a sensory distribution. TheLFCN passes between the psoas and quadratus lumborum muscles in the iliac fossa and enters the thigh under the inguinal ligament by passing through the anterior superior iliac spine over the iliacus muscle. It superficially spreads over the sartorius muscle and receives sensation in the anterolateral thigh. Ultrasonography (US) is frequently used by physiatrists in the diagnosis and interventional treatment of musculoskeletal diseases. MP is usually diagnosed with clinical symptoms such as burning, tingling, pain, and dysesthesia in the anterolateral thigh. Electromyography, US, and magnetic resonance imaging are helpful in diagnosis. US is an easy-to-apply, inexpensive method in daily practice, providing great comfort to clinicians in determining etiology and differential diagnosis. Treatment may include patient education, avoiding tight belts, losing weight, conservative treatment methods, use of non-steroidal anti-inflammatory drugs, local anesthetic and/or steroid injections, surgical neurectomy, neurolysis or transpositions. However, in recent years, there have been case series showing that radiofrequency ablation (RF) can also be applied. The aim of this study is to compare the effectiveness of RF ablation of the lateral femoral cutaneous nerve with steroid injection in patients with clinically diagnosed MP and confirmed by US.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Conservative Treatment and Ultrasound Guided Injection for Treatment Meralgia Paresthetica

NCT04004052

Meralgia Paresthetica

COMPLETED NA

Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries

NCT06809842

Analgesia Vastus Lateralis Nerve Block Lateral Femoral Cutaneous Nerve Block +1 more

RECRUITING NA

Paramedian CESI vs Selective Nerve Root PRF for Lower Cervical Radicular Pain

NCT05950321

Neck Pain Cervical Radiculopathy

COMPLETED NA

Comparing Ways to Freeze the Nerve That Provides Thigh Sensation

NCT02577510

Meralgia Paresthetica

COMPLETED PHASE3

Injections in the Diagnosis and Treatment of Lumbar Facet Syndrome

NCT03871192

Facet Joint Pain Facet Syndrome of Lumbar Spine Facet Joints; Degeneration

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meralgia Paresthetica

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulsed Radiofrequency Ablation

The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.

Group Type ACTIVE_COMPARATOR

No interventions assigned to this group

Steroid Injection

Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.

Group Type ACTIVE_COMPARATOR

Steroid (dexamethasone) Injection

Intervention Type DRUG

Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulsed Radiofrequency Ablation

The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.

Intervention Type PROCEDURE

Steroid (dexamethasone) Injection

Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with numbness, tingling and pain in the anterolateral thigh region
* Patients with edematous LFCN observed on ultrasound and diagnosed with MP and with complaints resistant to conservative treatment
* Being literate

Exclusion Criteria

* History of lumbar discopathy or history of discopathy surgery
* Cardiac pacemaker
* History of bilateral hip, knee, foot and lumbar region fractures
* History of previous hip and knee surgery
* Fixed joint contracture in the lower extremity
* History of malignancy and chemotherapy or radiotherapy
* Presence of any neuromuscular disease
* Progressive or non-progressive central and peripheral nervous system disease
* Patients in pregnancy and lactation
* Bleeding diathesis, INR\>1.2
* Uncontrolled diabetes or other serious comorbidities
* Allergy to drugs or materials used
* Local infections or sepsis

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No